Justin Faden is a Psychiatry physician affiliated with Rowan University. OpenAlex indexes 38 publications with 557 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2250 Chapel Ave W
Cherry Hill, NJ 080022051
Telephone
856-482-9000Provider last certified this registry record 2 Sept 2022.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Luye Pharma (USA) Ltd.Program year202532 payments$28,598openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202510 payments
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Atypical Antipsychotic100%Olanzapine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I
Journal of Clinical Psychopharmacology
2025 - Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
Journal of Clinical Psychopharmacology
2025 - Long‐Acting Injectables: A Strategy to Mitigate Nonadherence in Bipolar Disorder
Bipolar Disorders
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Lee Brooks, MD
Rowan University
Swagoto Mukhopadhyay, MD
Rowan University
Narsimha Pinninti, MD
Rowan University
Eric Nagele
Rowan University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”